MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Melanoma Res
Main Authors: Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Giancarlo, Masedu, Francesco, Deraco, Marcello, De Manzoni, Giovanni, Chiominto, Alessandro, Valenti, Marco, Pellegrini, Cristina
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2017
Assuntos:
ORIGINAL ARTICLES: Translational research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592983/
https://ncbi.nlm.nih.gov/pubmed/28486243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000367
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados